{"id":1700,"date":"2021-09-22T10:12:22","date_gmt":"2021-09-22T08:12:22","guid":{"rendered":"https:\/\/www.euromedlab2021munich.org\/?page_id=1700"},"modified":"2022-04-06T11:36:52","modified_gmt":"2022-04-06T09:36:52","slug":"educational-workshop","status":"publish","type":"page","link":"https:\/\/www.euromedlab2021munich.org\/index.php\/educational-workshop\/","title":{"rendered":"Educational Workshops"},"content":{"rendered":"

[vc_row][vc_column][vc_accordion active_tab=”1″ collapsible=”yes” style=”2″][vc_accordion_tab title=”DAY 2″]

<\/div>

Monday, 11 April<\/h2><\/div><\/div>
    \n
  • EDUW 1 – 14.00-15.00 SIEMENS HEALTHINEERS <\/strong> | Room 1<\/span>
    \nTitle: High Sensitivity cardiac Troponin I: Central lab or POC, the choice is yours
    \nChair: Alessandro Ortisi – Siemens Healthineers, Associate Director Global Clinical Marketing
    \nSpeakers:
    \nJohannes Neumann, MD – Department of Cardiology, University Heart and Vascular Center Hamburg, German Center for Cardiovascular Research (DZHK), Hamburg, Germany
    \nTitle: Evaluation of patients with suspected myocardial infarction
    \nNils A. S\u00f6rensen MD – Department of Cardiology, University Heart and Vascular Center Hamburg, German Center for Cardiovascular Research (DZHK), Hamburg, Germany
    \nTitle: High-sensitivity point-of-care troponin testing
    \nLearning Objectives:
    \n\u2022 Understand diagnostic steps required in patients with suspected myocardial infarction
    \n\u2022 Learn about diagnostic algorithms using high-sensitivity troponin assays
    \n\u2022 Learn about novel diagnostic strategies using point-of-care assays<\/li>\n
  • EDUW 3 – 14.00-15.00 ABBOTT <\/strong>| Room 13a<\/span>
    \nTitle: Novel Blood Tests for Game-Changing Detection and Treatment of Traumatic Brain Injury
    \nChair: Dr. Alex Carterson \u2013 DVP Medical, Clinical and Scientific Affairs, Abbott
    \nSpeakers:
    \nPeter Biberthaler, MD – Chair, Department of Trauma Surgery, Technical University Munich
    \nTitle: Diagnostic Dilemma of mild Traumatic Brain Injury
    \nBeth McQuiston, MD – Senior Medical Director, Abbott
    \nTitle: Traumatic Brain Injury: State of the Art Management
    \nLearning objectives:
    \n\u2022 Recognize the crucial unmet need for improved brain health assessment
    \n\u2022 Appreciate the objective value of GFAP (Glial Fibrillary Acidic Protein) and UCH-L1 (plasma ubiquitin C-terminal hydrolase-L1) as new game-changing tests that help clinicians evaluate the brain and optimize care pathways for traumatic brain injury
    \n\u2022 Identify collaborative opportunities to achieve measurably better outcomes related to TBI (Traumatic Brain Injury) for patients, payors clinicians and health systems.<\/li>\n
  • EDUW 4 – 14.00-15.00 SYSMEX<\/strong> | Room 13b<\/span>
    \nTitle: Providing clinical answers with innovative technology
    \nChair: Dr. Ondrej Valina – Sysmex Europe GmbH
    \nSpeakers:
    \nPD Dr. Mathias Zimmermann, DRK Kliniken Berlin, Germany
    \nProf. Johan Elf, University Uppsala, Sweden
    \nLearning objectives: Sysmex as an IVD manufacturer is aware about diagnostic challenges of clinicians in everyday routine. This workshop will review the current practice in infection diagnostics (performance and availability of biomarkers and lab tests) and present products and technologies from haematology and point-of care that can close gaps in diagnostic information. The learning objective is to create awareness for already available and future innovative products with the aim to improve healthcare.<\/li>\n
  • EDUW 5 – 14.00-15.00 ROCHE <\/strong>| Room 14a<\/span>
    \nTitle: Pandemic Preparedness
    \nChair: Dr. Christian Simon, Roche Diagnostics
    \nSpeakers:
    \nPD.Dr.med. Andreas Wieser, Global Health & Infectious Diseases at the Medical Center of the University of Munich
    \nTitle: Fighting Emerging Pathogens \u2013 the COVID Pandemic response in Germany
    \nProf.Dr.med. Stefan Holdenrieder, Director of the Institute of Laboratory Medicine, German Heart Center of the Technical University Munich
    \nTitle: Diagnostic follow-up in a post vaccine setting
    \nLearning objectives:
    \nWe\u2019re now almost two years on since the COVID-19 pandemic first hit and yet great uncertainty remains. Whilst there has been huge progress in terms of vaccine development and administration, less than a third of the world\u2019s population has received one or more doses of a SARS-CoV-2 vaccine, and there is great variation between countries. As new strains of the virus develop, we must aim for complete vaccine coverage, else we leave ourselves collectively exposed. And as the virus adapts, so must our communal response. To date we have led with social distancing measures and lockdown legislations, but reliable antibody testing enables widespread mass screening that – in combination with local and national policies \u2013 can modify and optimize restriction strategies. The information collected can also help scientists assess the exposure of different populations and levels of disease burden so that they can begin to predict its spread. The resulting insights can be used to inform strategies aiming to further contain and counter the virus, optimize governmental responses and ready health services so they are better able to cater to the needs of the people they serve.<\/li>\n
  • EDUW 6 – 15.30-16.30 MINDRAY <\/strong>| Room 5<\/span>
    \nTitle: The pre-classification of digitized images from peripheral blood
    \nChairs: Giuseppe D\u2019Onofrio – Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy
    \nFrancesca Mancini \u2013 Policlinico Umberto 1, Rome, Italy
    \nSpeaker:
    \nGina Zini – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
    \nTitle: The pre-classification of digitized images from peripheral blood
    \nLearning objective:
    \nMorphological evaluation of peripheral blood (PB) and bone marrow (BM) blood cells through optical microscopic (OM) examination remains a cornerstone in hematological diagnosis.
    \nThe development of digitized cell images technology and the current availability of systems capable of pre-classifying digitized blood cell images from PB smears offers practical possibilities of clinical applications and new opportunities in the hematology laboratory practice.
    \nIn this workshop comparison between morphology under OM and digitized morphology pre-classification on PB smears from onco-hematological patients will be presented.<\/li>\n
  • EDUW 7 – 15.30-16.30 SYSMEX <\/strong>| Room 13a<\/span>
    \nTitle: Let your lab workflow. Striving for operational excellence.
    \nChair: Maros Heidinger – Sysmex Europe GmbH
    \nSpeakers:
    \nRexhina Cipi, Germany – Sysmex Europe GmbH
    \nJohanna Engelage, Germany – Sysmex Europe GmbH
    \nTanja Tornow, Germany – Sysmex Europe GmbH
    \nLearning objecticves:
    \nWhen designing a specific work area in the laboratory, one of the challenges is to consider the surrounding processes while targeting their significant improvement, and the selection of a specific analyser configuration best possible supporting the key improvement points and KPIs defined by the laboratory. For decades, the Lean methodology has offered the respective tools and procedures for identifying and eliminating waste in processes. This workshop demonstrates the application of the Lean methodology to specific work areas with the aim to identify optimisation potential by eliminating waste and present solutions specifically addressing the identified optimisation potential.<\/li>\n
  • EDUW 8 – 15.30-16.30 WATERS <\/strong>| Room 13b<\/span>
    \nTitle: The role of LC-MS in a clinical laboratory
    \nSpeakers:
    \nBenjamin Dugas, Senior Global Marketing Manager Clinical Diagnostics
    \nGodo Bosch, Director Strategic Development Clinical Markets, EMEA
    \nDietmar Meyer, Project Manager R&D, RECIPE Chemicals + Instruments GmbH
    \nLearning objectives:
    \nWhile Immunoassays play a central role in Clinical Laboratories some needs have required the search for new technologies. We will discuss what Liquid Chromatography with Mass Spectrometry (LC-MS) is, what it brings to the laboratory and how it complements Immunoassays.
    \nExamples in routine work such as Endocrinology and Therapeutic Drug Monitoring assays will support the discussion. A short look at future possibilities will also be exposed with SARS CoV2 virus measurements.<\/li>\n
  • EDUW 9 – 15.30-16.30 SNIBE <\/strong>| Room 14a<\/span>
    \nTitle: New insights in immunoassays
    \nChair: Prof. Mario Plebani
    \nSpeakers:
    \nProf. Mario Plebani (Department of Laboratory Medicine, University Hospital of Padova, Italy)
    \nTitle: SARS-CoV- 2 antibodies testing: why, when and how?
    \nProf. J\u00e1nos Kappelmayer (Department of Laboratory Medicine, University of Debrecen, Hungary)
    \nTitle: Experience with AMH and Tacrolimus measurements on the MAGLUMI 800 analyzer
    \nLearning objectives:
    \nThe main learning objective of the workshop is to offer an update in the field of immunoassays.
    \nImmunoassays still play a central role in laboratory medicine, but some issues require further efforts:
    \n\u2022 Harmonization and standardization
    \n\u2022 Immunoassays versus mass spectrometry
    \n\u2022 Biological function versus mass concentration: the case of SARS-CoV-2 neutralizing antibodies<\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”DAY 3″]
    <\/div>

    Tuesday, 12 April<\/h2><\/div><\/div>
      \n
    • EDUW 15 – 14.00-15.00 ORTHO CLINICAL DIAGNOSTICS<\/strong>| Room 1<\/span>
      \nTitle: Chimeric Antigen Receptor (CAR)-T cell therapy: research findings, clinical applications, and markers to control cytokine release syndrome
      \nChair: Els Melis, EMEA Senior Marketing Manager Clinical Labs Assays, Ortho Clinical Diagnostics
      \nSpeakers:
      \nProf. \u00c1lvaro Urbano Ispizua, Director of the Institute of Hematology and Oncology of Hospital Cl\u00ednic Barcelona and Full Professor of Medicine at the University of Barcelona.
      \nTitle: Chimeric Antigen Receptor (CAR) – T cell therapy: from immunotherapy research to clinical applications in cancer treatment.
      \nCecilia Scarponi, EMEA Clinical Liaison, Ortho Clinical Diagnostics
      \nTitle: Laboratory biomarkers for the investigation of CAR-T cells toxicity.
      \nLearning objectives:
      \n\u2022 The immunotherapy: mechanisms of action and targeted hematological malignancies
      \n\u2022 The Patient: successful treatments and strategies to overcome side effects
      \n\u2022 How laboratory tests can contribute to a favorable patient outcome? Which biomarkers are currently of interest to assess cytokine release syndrome and neurotoxicity associated with CAR-T cell therapy?<\/li>\n
    • EDUW 17 – 14.00-15.00 ABBOTT<\/strong>| Room 13a<\/span>
      \nTitle: Achieving Measurably Better Healthcare\u2026 How to get started and achieve success through integrated clinical care initiatives
      \nSpeakers:
      \nTricia Ravalico – Director, Scientific Leadership and Education for Abbott, Core Diagnostics Executive Lead, UNIVANTS of Healthcare Excellence Program
      \nMaria Salinas, PhD – Head of Laboratory, Hospital Universitari Saint Joan d\u2019Alacant, Spain- 2020 UNIVANTS of Healthcare Excellence Global Winner
      \nRana Nabulsi, MD – Head Consultant on Healthcare Quality, Dubai Health Authority, UAE – 2020 UNIVANTS of Healthcare Excellence Awards, Global Distinction and Best of the Middle East
      \nLearning objectives:
      \n\u2022 Recognize, appreciate and emulate critical success factors and key attributes across successful integrated clinical care teams
      \n\u2022 Define relevant key performance indicators that can be influenced and impacted by laboratory medicine and pathology leadership
      \n\u2022 Highlight successful examples of award-winning best practices related to the Diabetes epidemic and COVID-19 pandemic.
      \n\u2022 Identify opportunities to achieve and be recognized for measurably better healthcare performance<\/li>\n
    • EDUW 18 – 14.00-15.00 SYSMEX<\/strong>| Room 13b<\/span>
      \nTitle: Towards a smarter lab with digitally enhanced solutions
      \nChair: Theo Hofman – Sysmex Europe GmbH
      \nSpeakers:
      \nDr. Jean-Marc Giannoli – Biogroup Laboratories, Neuville-sur-Sa\u00f4ne, France
      \nTitle: Value of combining QC and patient results for decision support on analytical performance
      \nDr. Patrick Cohen – Geneva University Hospital, Switzerland
      \nTitle: Biomedical insights beyond the numbers
      \nKoray Yurdakul, Sysmex Turkey
      \nTitle: Leveraging virtual and mobile learning experiences in healthcare
      \nLearning objectives:
      \nIn the laboratory of today, besides global challenges, many regulatory and organisational demands impact the daily work. Oftentimes it can be perceived as a burden, but it also gives new opportunities to improve the laboratory\u2019s quality, streamline processes and find ways to do things differently. With digitally enhanced solutions, information from multiple sources can be consolidated easily for a more holistic approach and lead to new insights. In this workshop, the synergy between existing and new cornerstones of monitoring the quality of analytical processes is demonstrated, explained how the use of expert software can support in clinical decision making and in which ways digital learning experiences can bring and maintain the knowledge of the laboratory staff on a high level while saving time and costs and reduce environmental impact.<\/li>\n
    • EDUW 19 – 14.00-15.00 ROCHE<\/strong>| Room 14a<\/span>
      \nTitle: Diagnostic Innovation Drivers
      \nChair: Victor Jeger, PD Dr.med. MD, PhD, Roche Diagnostics
      \nSpeakers:
      \nProf. Dr. med. Michael Vogeser, Institute of Laboratory Medicine, Hospital University of Munich, Germany
      \nTitle: Use of Mass Spectrometry in Clinical Diagnostics
      \nProf. Prof. Charlotte Teunissen, Universitair Medische Centra Amsterdam, The Netherlands
      \nTitle: Timely and accurate differential diagnosis of patients with cognitive impairment
      \nLearning objectives:
      \nMass spectrometry is a powerful analytical technology that has evolved from a research tool to a complementary platform in routine clinical laboratories. Unlike established methods such as immunoassays, MS allows true multiplexing, highest specificity of detection and unsurpassed reliability due to the use of standard compounds labelled with stable isotopes. With increasing clinical applications, the focus is on clinical chemistry and more recently microbiology. The main objective of this presentation is to give an overview of the current and developing clinical applications of MS.
      \nDementia affects millions of people worldwide and is expected to triple by 2050. Alzheimer\u2019s disease (AD) is the most common form of dementia and may contribute to 50-60% of cases. In 2015 the overall global cost of dementia was already USD 818 billion and is expected to increase to USD 2 trillion in 2030. Early diagnosis can benefit patients and society as a whole. Confirming a diagnosis of mild cognitive impairment (MCI) and Alzheimer\u2019s disease (AD) is important and often a relief for the individual and their loved ones. Receiving a diagnosis early enables patients to make changes to their diet and lifestyles which may slow the decline in their cognitive functions. Two of the main hallmark signs of AD are the “plaques” and “tangles” that develop in the brain, caused by the build-up of, respectively, amyloid and tau proteins. The accumulation of amyloid beta and tau starts decades prior to symptom onset. CSF biomarkers support early and accurate diagnosis of MCI and AD, as these biomarkers reflect the specific pathological accumulation of amyloid beta in plaques and tau in neurofibrillary tangles.<\/li>\n
    • EDUW 20 – 15.30-16.30 MINDRAY<\/strong>| Room 5<\/span>
      \nTitle: Presepsin and new generation inflammatory biomarkers in COVID-19 and other infections
      \nChairs: Massimiliano M. Corsi Romanelli – Universit\u00e0 degli Studi di Milano, Milan, Italy
      \nAntonio Brattoli – Mindray Medical Italy S.R.L., Milan, Italy
      \nSpeaker:
      \nEmanuela Galliera – Universit\u00e0 degli Studi di Milano, Milan, Italy
      \nTitle: Presepsin and new generation inflammatory biomarkers in COVID-19 and other infections
      \nLearning objectives:
      \nThe appropriate identification of infection is the basis for effective treatment and control of infective diseases. Presepsin (PSP), an emerging biomarker of infection, has been recently described as early marker of different infections.
      \nThis workshop will present the evaluation of Presepsin, in correlation with new inflammatory markers, cytokine storm molecules and current inflammatory parameters (IL-6, IL-10, SuPAR and sRAGE), in order to define a panel of biomarkers that could be useful for a better prognostic prediction of COVID-19 mortality.<\/li>\n
    • EDUW 21 – 15.30-16.30 GMT Science<\/strong>| Room 13a<\/span>
      \nTitle: Faecal metagenomics analysis made available at the medical lab to empower clinical diagnosis & management
      \nChair: Etienne Formstecher – CEO, GMT, Paris, France
      \nSpeakers:
      \nFay Betsou \u2013 Scientific Advisor, Laboratoire National de Sant\u00e9, Luxembourg
      \nTitle: In practice: setting up faecal metagenomics analyses at the medical laboratory
      \nFrancisco Guarner \u2013 Member of the Digestive System Research Unit, University Hospital Vall d\u2019Hebron; Consultant of Gastroenterology, Teknon Medical Centre, Barcelona, Spain
      \nTitle: Microbiota: a key player in physiology and pathophysiology
      \nLearning objectives:
      \nThe gut microbiota is now recognized as a novel therapeutic target in many clinical contexts.
      \nHowever, due to the lack of a reliable tool to characterize it, the proposed treatments can neither be adapted to the specific needs of the patient nor evaluated in terms of response.
      \nThe educational workshop will present how analysis of the faecal metagenome at the medical laboratory is now possible thanks to the combination of reliable, standardized and reproducible pre-analytical and analytical techniques with robust bioinformatics methods. By putting in place this solution, , medical laboratories can empower clinical diagnosis and management in various situations, including very common ones at the medical consultation where patients express gut complaints.<\/li>\n
    • EDUW 22 – 15.30-16.30 SEBIA<\/strong>| Room 13b<\/span>
      \nTitle: What\u2019s new in Minimal Residual Disease testing for Multiple Myeloma?
      \nChair: Dr. Martijn VAN DUIJN, Erasmus Medical Center, Rotterdam, The Netherlands
      \nSpeakers:
      \nDr. Thomas DEJOIE, Biochemical Laboratory, University Hospital of Nantes, France
      \nTitle: Overview of MRD testing in Myeloma and current needs
      \nDr. Hans JACOBS, Radboud University Medical Center, Nijmegen, The Netherlands
      \nTitle: Mass spectrometry as a tool for MRD detection in the blood of Myeloma patients
      \nLearning objectives:
      \n\u2022 Why do we need MRD for patients?
      \n\u2022 How do we process MRD in 2021?
      \n\u2022 Why do we need alternative to the MRD bone marrow evaluation?
      \n\u2022 Understand the principle of mass spectrometric measurements of clonotypic peptides
      \n(bottom-up MS).<\/li>\n
    • EDUW 23 – 15.30-16.30 SNIBE<\/strong>| Room 14a<\/span>
      \nTitle: An update on tumor markers from the general aspects to their clinical uses
      \nChair: Prof. Tomris Ozben
      \nSpeakers:
      \nProf. Tom\u00e1\u0161 Zima (Institute of Clinical Chemistry & Laboratory Diagnosis. First Faculty of Medicine Charles University Prague – Czech Republic)
      \nTitle: Classification of tumor markers. Characteristics of ideal tumor markers
      \nProf. Tomris Ozben (Dept. of Clinical Biochemistry, Medical Faculty, University of Akdeniz, Antalya, Turkey)
      \nTitle: Methods to measure tumor markers. Clinical uses of tumor markers for malignant diseases
      \nLearning objectives:
      \nTumor markers are used to determine risk, screen for early cancers, establish diagnosis, follow prognosis, predict the efficiency of a specific therapy, and monitor for disease recurrence.
      \n\u2022 Classification of tumor markers based on category, origin, structure, biological function in tumor growth or formation
      \n\u2022 Characteristics of ideal tumor markers
      \n\u2022 Methods to measure tumor markers
      \n\u2022 Limitations of tumor marker tests
      \n\u2022 Benign conditions associated with rise in tumor markers
      \nClinical uses of tumor markers for malignant diseases (clinical cases)<\/li>\n
    • EDUW 26 – 17.00-18.00 SIEMENS HEALTHINEERS<\/strong>| Room 13b<\/span>
      \nTitle: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases
      \nChair: Jean Charles Clouet \u2013 Siemens Healthineers, EMEA Clinical Marketing
      \nSpeaker:
      \nProfessor J\u00f6rn M. Schattenberg – Metabolic Liver Research Program, University Medical Center Mainz
      \nLearning Objectives:
      \n\u2022 Educate on the current growing burden of disease due to NAFLD\/NASH
      \n\u2022 Learn how non-invasive testing can help identify patients at risk of NASH progression
      \n\u2022 Understand how clinicians can implement available patient pathways to improve referrals and decrease costs<\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”DAY 4″]
      <\/div>

      Wednesday, 13 April<\/h2><\/div><\/div>
        \n
      • EDUW 29 – 14.00-15.00 ORTHO CLINICAL DIAGNOSTICS<\/strong> | Room 1<\/span>
        \nTitle: Sustainable Laboratory Medicine: Prepare for the future now!
        \nChair: Dr. Bernard Gouget, Ph.D \u2013 ex-Assistant Professor, University Hospital in Paris Descartes. President-Healthcare Division Executive Committee, Comit\u00e9 Fran\u00e7ais d\u2019accr\u00e9ditation (Cofrac), President, National Committee for the selection of Reference Laboratories, Ministry of Health
        \nSpeakers:
        \nProfessor Damien Gruson \u2013 Head of the department of Laboratory Medicine of the Cliniques Universitaires Saint Luc \u2013 Brussels, Belgium
        \nTitle: Sustainable Laboratory Medicine: Myth or reality?
        \nJordi Traf\u00ed-Prats \u2013 Senior Director EMEA Marketing at Ortho Clinical Diagnostics
        \nTitle: Sustainable Laboratory Medicine: we all have a role to play.
        \nLearning objectives:
        \nIn the coming years, the impact of sustainability will be increasingly felt in healthcare. From the implications of legislation to the growing number of environmentally conscious investors, this is a topic which is set to shape the future direction of hospitals, labs and blood banks.
        \nProfessor Damien Gruson as a member of the Division on Emerging Technologies of IFCC, is sharing his perspective and will be providing some pragmatic approaches and share experiences from the perspective of the Clinical Laboratory. Jordi Traf\u00ed-Prats will demonstrate how the industry can and should contribute to assure Laboratories are equipped with sustainable solutions.<\/li>\n
      • EDUW 31 – 14.00-15.00 ABBOTT<\/strong> | Room 13a<\/span>
        \nTitle: Driving Healthcare Transformation Through Clinical Decision Support
        \nSpeakers:
        \nDr Janne Cadamuro – Department of Laboratory Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria
        \nTitle: How to tackle laboratory underuse using Clinical Decision Support Systems (CDSS)
        \nFrancoise Luyckx – Pharmacist biologist, Laboratory Manager and Coordinator of new projects, member of the “Artificial Intelligence” working group, Coordinator of CDS project and IT trainer, University Hospital of Liege (CHU de Li\u00e8ge), Belgium
        \nRomy Gadisseur – Pharmacist biologist, Head of the Laboratory of Automated Biochemistry, Department of Clinical Chemistry, University Hospital of Liege (CHU de Li\u00e8ge), Belgium
        \nTitle: CHU Liege: Impacting CKD patients by leveraging a Clinical Decision Support
        \nAbbott Speaker
        \nFlorian Lange, Director AlinIQ & Enterprise Solutions EMEA
        \nTitle: Transformation of healthcare through digital solutions
        \nLearning objectives:
        \n\u2022 Recognize the value of clinical decision support and artificial intelligence in achieving measurable better healthcare.
        \n\u2022 Understand how the use of a clinical decision support solution enabled the University Hospital of Salzburg and in CHU Liege to address unmet needs for microcytic anaemia, diabetes and chronic kidney disease.
        \n\u2022 Connect the dots on how to get started and drive digital transformation into better healthcare outcomes<\/li>\n
      • EDUW 32 – 14.00-15.00 SIEMENS HEALTHINEERS<\/strong> | Room 13b<\/span>
        \nTitle: The Evolving Role of Artificial Intelligence in Laboratory Testing
        \nSpeakers:
        \nRaj Gopalan, MD, MSIS, Head of Global Clinical Decision Support and Chief Medical Informatics Officer, Siemens Healthineers, Tarrytown, NY, USA
        \nSarah Wheeler, Assistant Professor, PhD, FACB, CC, Associate Medical Director, Clinical Immunopathology; Medical Director, Automated Laboratory, UPMC Mercy; and Medical Director, Automated Laboratory, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
        \nLearning Objectives:
        \n\u2022 Define artificial intelligence and machine learning in the context of laboratory medicine.
        \n\u2022 Discuss the relevance of artificial intelligence and machine learning in laboratory medicine and diagnostics.
        \n\u2022 Understand the potential value of artificial intelligence in laboratory diagnostics.<\/li>\n
      • EDUW 33 – 14.00-15.00 ROCHE<\/strong> | Room 14a<\/span>
        \nTitle: Diabets and the heart
        \nChair: Rolf Hinzmann, MD, PhD, Head of Medical Science – Roche Diabetes Care, Mannheim, Germany
        \nSpeakers:
        \nProf. Christophe Meune, M.D., PhD, Cardiology Department, Avicenne University Hospital, Paris, France
        \nTitle: Early identification of Heart Failure in T2D; Intervention for improving patient outcomes
        \nProf.Dr. Stephan Jacob \u2013 Praxis f\u00fcr Pr\u00e4vention und Therapie, Villingen-Schwenningen, Germany
        \nTitle: Integrated Personal Diabetes Management
        \nLearning Objectives:
        \nFor many years, clinical studies could not show that lowering glucose in patients with type 2 diabetes leads to better macrovascular outcomes. In the past few years, new data have shown that treatment with two classes of dugs developed as “glucose-lowering agents,” SGLT2 inhibitors and GLP-1 receptor agonists can reduce macrovascular and renal complications. These studies have prompted debate about the main aim of type 2 diabetes management. In this scientific session eras of diabetes management are described according to the treatment recommendations, moving from a pure glucocentric view into the present cardio-renal outcome-oriented approach, this has been endorsed by major diabetes and cardiology societies. Type 2 Diabetes Patients are at high risk of developing cardiovascular disease. New evidence on the use of natriuretic peptides supports the identification of patients with high cardiovascular risk, for risk stratification and optimization of cardio protective treatment.<\/li>\n
      • EDUW 35 – 15.30-16.30 BD<\/strong> | Room 13a<\/span>
        \nTitle: Preanalytical POCT Errors \u2013 What impact do they have?
        \nChair: Dr Brendan Meyer – Senior Manager, Medical Affairs Europe, Integrated Diagnostic Solutions, BD Life Sciences
        \nSpeakers:
        \nProf Peter Luppa – Institute for Clinical Chemistry and Pathobiochemistry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany
        \nDr Andrei Tintu – Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
        \nDr Antonio Bu\u00f1o Soto – Pathology Department, La Paz Hospital, Madrid, Spain
        \nLearning objectives:
        \n\u2022 There are erroneous POCT results due to blood sample quality, which are not detected by the POCT device.
        \n\u2022 How preanalytical errors not detected by the POCT device can impact on patient care.
        \n\u2022 POCT preanalytical errors can impact on hospital resources and budgets<\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

        [vc_row][vc_column][vc_accordion active_tab=”1″ collapsible=”yes” style=”2″][vc_accordion_tab title=”DAY 2″][\/vc_accordion_tab][vc_accordion_tab title=”DAY 3″][\/vc_accordion_tab][vc_accordion_tab title=”DAY 4″][\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/pages\/1700"}],"collection":[{"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/comments?post=1700"}],"version-history":[{"count":5,"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/pages\/1700\/revisions"}],"predecessor-version":[{"id":1998,"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/pages\/1700\/revisions\/1998"}],"wp:attachment":[{"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/media?parent=1700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}